Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 78

Results For "Support"

3632 News Found

Lifecore Biomedical teams up with Indomo to advance at-home acne therapy
Biopharma | March 10, 2026

Lifecore Biomedical teams up with Indomo to advance at-home acne therapy

Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation


Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development
News | March 10, 2026

Hopewell Therapeutics sublicenses breakthrough LNP technology to Foxcroft for cancer vaccine development

The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications


Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
News | March 10, 2026

Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens

The first of four planned modules at the new plant is expected to come online by summer 2026


Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India
News | March 10, 2026

Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India

Huwel’s diagnostic solutions leverage open RT-PCR system


Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer
Biotech | March 10, 2026

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients


AbbVie reports promising early results for novel obesity therapy ABBV-295
News | March 10, 2026

AbbVie reports promising early results for novel obesity therapy ABBV-295

ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks


FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer
News | March 10, 2026

FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer

Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population